This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
1 Regulators invest significant consideration balancing quality-of-life measures with overall survival when assessing novel oncology treatments. In practice, some patients may be left managing a syndrome associated with the therapy along with the disease. 3D rendering of Antibody Drug Conjugate Molecules.
Obtaining adequate drug exposure in the brain is key to treating CNS diseases effectively. The BBB is composed of specialized brain endothelial cells that regulate the distribution of molecules into and out of the brain from the blood. Recently, Dennis Koester gave us a crash course in CNS drug discovery in a Drug Hunter Flash Talk.
He studies the genetics of numerous common diseases, particularly neuropsychiatric genetics especially schizophrenia, autism, and ADHD. His research focuses on the function of synapses and their disruption in animal models (especially non human primate models) of neurodevelopmental and psychiatric disease.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content